Literature DB >> 9431391

Interactions between tacrolimus and antimicrobial agents.

D L Paterson1, N Singh.   

Abstract

Tacrolimus is being increasingly used as an immunosuppressive agent in transplant recipients. The drug is metabolized by the cytochrome P-450 3A system, thus antimicrobials that inhibit or induce these enzymes can alter levels of tacrolimus in the bloodstream. Tacrolimus is potentially nephrotoxic and neurotoxic; the likelihood of toxicity rises as blood levels of the drug increase. Increased tacrolimus levels and subsequent toxicity have been produced by a number of antimicrobial agents that inhibit the cytochrome P-450 3A system. Conversely, drugs with the potential to induce the cytochrome P-450 3A system can reduce the levels of tacrolimus in the blood, leading to increased risk of acute rejection in transplant recipients. Antimicrobial agents that can have adverse effects on renal function may add to the nephrotoxicity of tacrolimus. The potential for drug interactions should be reviewed before antimicrobial agents are prescribed to patients treated with tacrolimus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9431391     DOI: 10.1086/516138

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  14 in total

Review 1.  Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU.

Authors:  Isabel Spriet; Wouter Meersseman; Jan de Hoon; Sandrina von Winckelmann; Alexander Wilmer; Ludo Willems
Journal:  Intensive Care Med       Date:  2009-01-09       Impact factor: 17.440

2.  Dosing equation for tacrolimus using genetic variants and clinical factors.

Authors:  Chaitali Passey; Angela K Birnbaum; Richard C Brundage; William S Oetting; Ajay K Israni; Pamala A Jacobson
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

3.  Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir.

Authors:  Markus Bickel; Evrim Anadol; Martin Vogel; Wolf Peter Hofmann; Nils von Hentig; Johannes Kuetscher; Michael Kurowski; Christian Moench; Tessa Lennemann; Thomas Lutz; Wolf Otto Bechstein; Hans Reinhard Brodt; Jürgen Rockstroh
Journal:  J Antimicrob Chemother       Date:  2010-03-04       Impact factor: 5.790

4.  Tacrolimus variability is associated with de novo donor-specific antibody development in pediatric renal transplant recipients.

Authors:  Sonia Solomon; Adriana Colovai; Marcela Del Rio; Nicole Hayde
Journal:  Pediatr Nephrol       Date:  2019-11-15       Impact factor: 3.714

Review 5.  Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Authors:  Uwe Christians; Wolfgang Jacobsen; Leslie Z Benet; Alfonso Lampen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 6.  Infections caused by non-tuberculous mycobacteria in recipients of hematopoietic stem cell transplantation.

Authors:  Khalid Ahmed Al-Anazi; Asma M Al-Jasser; Waleed Khalid Al-Anazi
Journal:  Front Oncol       Date:  2014-11-10       Impact factor: 6.244

7.  High on Cannabis and Calcineurin Inhibitors: A Word of Warning in an Era of Legalized Marijuana.

Authors:  Naomi Hauser; Tanmay Sahai; Rocco Richards; Todd Roberts
Journal:  Case Rep Transplant       Date:  2016-08-09

8.  Outcomes Following Macrolide Use in Kidney Transplant Recipients.

Authors:  Rachel Jeong; Robert R Quinn; Krista L Lentine; Anita Lloyd; Pietro Ravani; Brenda Hemmelgarn; Branko Braam; Amit X Garg; Kevin Wen; Anita Wong-Chan; Sita Gourishankar; Ngan N Lam
Journal:  Can J Kidney Health Dis       Date:  2019-02-21

9.  Role of cytochrome P450 in drug interactions.

Authors:  Zakia Bibi
Journal:  Nutr Metab (Lond)       Date:  2008-10-18       Impact factor: 4.169

10.  Tacrolimus-induced Diabetic Ketoacidosis in a Polymyositis Patient Precipitated by Fluconazole: A Case Report and Review of the Literature.

Authors:  Hira Chaudhary; Shweta Kumar; Nagasudha L Chigurupati; Gregory A Chang; Gul Bahtiyar; Madina Abduraimova; Samy I McFarlane
Journal:  Am J Med Case Rep       Date:  2020-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.